Revolutionizing Healthcare.
For Patients, Providers, Pharma, and Payers.
A TechBio Company.
Our Purpose
As pioneers in the TechBio field, we envision a future where revolutionary intelligent solutions drive personalized medicine, significantly enhancing outcomes for patients, providers, pharma, and payers.
We create and commercialize closed-loop clinical care solutions with Generative AI, Multi-Modal Digital Biomarkers, and One-of-a-Kind Drug Delivery Devices, continuously improving outcomes and advancing the practice of personalized medicine. Our efforts also encompass business model innovation, focusing on reducing inefficiencies, lowering care delivery costs, and achieving better alignment across the value chain.
Discover Our Distinctive Approaches
Driving Innovation Across the Ecosystem
Our transdisciplinary team and collaborative partners research, develop, and commercialize closed-loop clinical care with distinctive approaches including:
We Use Distinctive Approaches and Are Committed to Innovative Solutions.
Our focal areas include pioneering science, cutting-edge engineering, risk-based development, and business model innovation.
Our Integrated Lifecycle
Regulated by the FDA and other global agencies, we operate as a combination product, Software as a Medical Device (SaMD), and medical device company, in full compliance with all relevant standards.
Our Products and Platforms
Personalizing Care For Patients and Providers
Research and Development
We are researching and developing closed-loop clinical care solutions for several therapeutic areas
Platform-Based Approach
Our platform-based approach allows us to support more patients and providers across multiple therapeutic areas.
Our Products and Platforms
Research and Development
We are researching and developing novel drug delivery devices, intelligent edge medical devices, intelligent decision support, and personalized precision dosing algorithms for several therapeutic areas. *
Platform-Based Approach
Our platform-based approach enables scalable development, cross-platform learnings, and shorter development cycles, thus allowing us to support more patients and providers across multiple therapeutic areas.
*Products in development are investigational products. FDA has not yet evaluated the safety or effectiveness of these products.